Isis Pharmaceuticals (ISIS) 57.56 $ISIS
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), AGN: 240.59 (+2.58), ABUS: 3.91 (-0.08), ACST: 1.30 (-0.02), ISIS: 57.56 (-0.28), AZN: 30.11 (unch), CBAY: 1.58 (-0.02)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.43 (unch), ISIS: 57.56 (-0.28), ONCE: 55.43 (+1.38), SHPG: 188.21 (-1.31), SCMP: 11.49 (+0.10), GNST: (), CLBS: 0.57 (+0.03)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 122.85 (+0.34), GBT: 17.62 (+0.56), ISIS: 57.56 (-0.28), GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), SGMO: 6.18 (+0.08), BMY: 75.28 (+1.20), NVS: 82.13 (+0.33), XLRN: 34.75 (+0.84)
Acromegaly - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcvj9g/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acromegaly Overview - Therapeutics Development - Pipeline Products for Acromegaly - Overview - Pipeline Products for Acromegaly - Comparative Analysis - Acromegaly - Therapeutics under Development by Companies - Acromegaly - Therapeutics under Investigation by Universities/Institutes - Acromegaly - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acromegaly - Products under Development by Companies - Acromegaly - Products under Investigation by Universities/Institutes - Acromegaly - Companies Involved in Therapeutics Development Companies Mentioned: - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Peptron, Inc. - Sompharmaceuticals S.A. - Strongbridge Biopharma plc For more information visit http://www.researchandmarkets.com/research/tcvj9g/acromegaly
ISIS: 57.56 (-0.28), SBBP: 3.76 (-0.06), CHMA: 2.98 (+0.10), NVS: 82.13 (+0.33)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.62 (+0.56), BCRX: 3.09 (+0.10), ISIS: 57.56 (-0.28), ARWR: 5.73 (+0.17), SHPG: 188.21 (-1.31), IBIO: 0.68 (unch), DYAX: 38.04 (-0.37)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.66 (+0.34), ISIS: 57.56 (-0.28), OPK: 9.87 (+0.01), ICPT: 151.73 (+7.98), XLRN: 34.75 (+0.84)
Global Venous Thromboembolism Therapeutics Pipeline Review 2015
M2 - Thu Jan 07, 10:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7p7ssr/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Venous Thromboembolism Overview - Therapeutics Development - Pipeline Products for Venous Thromboembolism - Overview - Pipeline Products for Venous Thromboembolism - Comparative Analysis - Venous Thromboembolism - Therapeutics under Development by Companies - Venous Thromboembolism - Therapeutics under Investigation by Universities/Institutes - Venous Thromboembolism - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Venous Thromboembolism - Products under Development by Companies - Venous Thromboembolism - Products under Investigation by Universities/Institutes - Venous Thromboembolism - Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/7p7ssr/venous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PTLA: 24.27 (+0.32), ISIS: 57.56 (-0.28), GLYC: 7.15 (+0.32)
Isis Pharmaceuticals to report change in name and ticker symbol
M2 - Mon Dec 21, 4:39AM CST
Isis Pharmaceuticals (NasdaqGS:ISIS) stated on Friday that it has changed its name to Ionis Pharmaceuticals effective December 2015.
ISIS: 57.56 (-0.28)
Isis Pharmaceuticals changes name to Ionis
AP - Fri Dec 18, 11:19AM CST
NEW YORK (AP) — Isis Pharmaceuticals Inc., which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting to do so for some time.
ISIS: 57.56 (-0.28)
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
PR Newswire - Fri Dec 18, 8:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced "eye-OH-nis"
Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases.
ISIS: 57.56 (-0.28)
Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
PR Newswire - Thu Dec 17, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston.
ISIS: 57.56 (-0.28)
Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Brian Orelli, The Motley Fool - Motley Fool - Mon Dec 14, 7:40PM CST
Next year is shaping up to be a great year for emerging biotech Alnylam Pharmaceuticals . The drugmaker expects to have 10 major clinical readouts in 2016. That's more than some one-drug-wonder biotechs have during their entire existence. The...
ISIS: 57.56 (-0.28), ALNY: 62.18 (+0.66)
7 Companies We'd Buy and Hold for the Next 20 Years
Dan Caplinger, Jason Hall, Andrés Cardenal, Steve Symington, Timothy Green, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Dec 14, 4:01PM CST
Many traders hope to get rich quick in the stock market, but over time, the best performance has come from long-term investors who choose companies that can produce solid returns year after year. The key is finding stocks that have the potential for...
AMZN: 745.81 (+9.24), ISIS: 57.56 (-0.28), IBM: 154.46 (+1.86), CMG: 399.71 (+8.93), XLK: 44.13 (+0.68), CVS: 96.74 (+1.24), MA: 88.56 (+0.75)
Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study
Zacks Equity Research - Zacks Investment Research - Mon Dec 14, 3:35PM CST
Isis Pharmaceuticals (ISIS) announced that Biogen has started a phase I/II study on ISIS-SOD1Rx for the treatment of patients with amyotrophic lateral sclerosis.
BIIB: 251.30 (+4.03), ISIS: 57.56 (-0.28), ACHN: 9.14 (+0.26), GSK: 43.38 (+0.04)
Isis Pharmaceuticals begins Phase 1/2 clinical study of ISIS-SOD1 Rx in ALS patients
M2 - Mon Dec 14, 5:10AM CST
Drug discovery company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the launch of a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS) by its partner, Biogen.
ISIS: 57.56 (-0.28)
World Amyloidosis Therapeutics Pipeline Report 2015 - 13 Companies & 25 Drug Profiles
M2 - Fri Dec 11, 6:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/65kjj8/amyloidosis) has announced the addition of the "Amyloidosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bellus Health Inc. - Bsim2 - Celgene Corporation - GlaxoSmithKline Plc - Isis Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - Prothena Corporation Plc - SOM Innovation Biotech SL Drug Profiles - ALN-TTRsc02 - Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - carfilzomib - CLR-01 - eprodisate disodium - GSK-2315698 GSK-2398852 - GSK-2398852 - ISIS-TTRRx - ixazomib citrate - LUNAR-101 - LUNAR-102 - Monoclonal Antibody for Amyloidosis - Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - NEOD-001 - NPT-005 - patisiran - pomalidomide - PTI-110 - revusiran - Small Molecules for AL Amyloidosis - Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - tafamidis meglumine - tolcapone For more information visit http://www.researchandmarkets.com/research/65...myloidosis
ISIS: 57.56 (-0.28), PFE: 36.12 (+0.35), GSK: 43.38 (+0.04), PRTA: 44.01 (+2.28), CELGZ: 1.43 (+0.08)
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
PR Newswire - Fri Dec 11, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis' strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, previously referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents approximately 10 percent of all cases of ALS. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.
ISIS: 57.56 (-0.28)
Positive Clinical Data Sends Isis Pharmaceuticals, Inc. Soaring in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 10, 7:28AM CST
Shares of Isis Pharmaceuticals , a predominantly clinical-stage antisense drug developer, soared 27% in November, based on data from S&P Capital IQ , after reporting an abundance of positive trial outcomes. The biggest boost for Isis...
BIIB: 251.30 (+4.03), ISIS: 57.56 (-0.28)
27.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Dec 09, 9:33AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on October 26th, 2015 at $45.88. In approximately 1 month, Isis Pharmaceuticals has returned 27.02% as of today's recent price of $58.27.
ISIS: 57.56 (-0.28)
Muscular Dystrophy Global Clinical Trials - Analysis, Review, Technologies & Forecast Report H2, 2015
M2 - Tue Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/nb9xbn/muscular) has announced the addition of the "Muscular Dystrophy Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Muscular Dystrophy Global Clinical Trials Review, H2, 2015" provides an overview of Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - aTyr Pharma, Inc. - Pfizer Inc. - Bioblast Pharma Ltd. - Santhera Pharmaceuticals Holding AG - Isis Pharmaceuticals, Inc. - Genethon - AMO Pharma Limited - Alkeus Pharmaceuticals, Inc. - Alfa Wassermann S.p.A - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/nb9xbn/muscular
ISIS: 57.56 (-0.28), PFE: 36.12 (+0.35), XLRN: 34.75 (+0.84)
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), AGN: 240.59 (+2.58), ABUS: 3.91 (-0.08), ACST: 1.30 (-0.02), ISIS: 57.56 (-0.28), AZN: 30.11 (unch), CBAY: 1.58 (-0.02)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.43 (unch), ISIS: 57.56 (-0.28), ONCE: 55.43 (+1.38), SHPG: 188.21 (-1.31), SCMP: 11.49 (+0.10), GNST: (), CLBS: 0.57 (+0.03)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 122.85 (+0.34), GBT: 17.62 (+0.56), ISIS: 57.56 (-0.28), GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), SGMO: 6.18 (+0.08), BMY: 75.28 (+1.20), NVS: 82.13 (+0.33), XLRN: 34.75 (+0.84)
Acromegaly - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcvj9g/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acromegaly Overview - Therapeutics Development - Pipeline Products for Acromegaly - Overview - Pipeline Products for Acromegaly - Comparative Analysis - Acromegaly - Therapeutics under Development by Companies - Acromegaly - Therapeutics under Investigation by Universities/Institutes - Acromegaly - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acromegaly - Products under Development by Companies - Acromegaly - Products under Investigation by Universities/Institutes - Acromegaly - Companies Involved in Therapeutics Development Companies Mentioned: - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Peptron, Inc. - Sompharmaceuticals S.A. - Strongbridge Biopharma plc For more information visit http://www.researchandmarkets.com/research/tcvj9g/acromegaly
ISIS: 57.56 (-0.28), SBBP: 3.76 (-0.06), CHMA: 2.98 (+0.10), NVS: 82.13 (+0.33)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.62 (+0.56), BCRX: 3.09 (+0.10), ISIS: 57.56 (-0.28), ARWR: 5.73 (+0.17), SHPG: 188.21 (-1.31), IBIO: 0.68 (unch), DYAX: 38.04 (-0.37)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.66 (+0.34), ISIS: 57.56 (-0.28), OPK: 9.87 (+0.01), ICPT: 151.73 (+7.98), XLRN: 34.75 (+0.84)
Global Venous Thromboembolism Therapeutics Pipeline Review 2015
M2 - Thu Jan 07, 10:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7p7ssr/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Venous Thromboembolism Overview - Therapeutics Development - Pipeline Products for Venous Thromboembolism - Overview - Pipeline Products for Venous Thromboembolism - Comparative Analysis - Venous Thromboembolism - Therapeutics under Development by Companies - Venous Thromboembolism - Therapeutics under Investigation by Universities/Institutes - Venous Thromboembolism - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Venous Thromboembolism - Products under Development by Companies - Venous Thromboembolism - Products under Investigation by Universities/Institutes - Venous Thromboembolism - Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/7p7ssr/venous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PTLA: 24.27 (+0.32), ISIS: 57.56 (-0.28), GLYC: 7.15 (+0.32)
Isis Pharmaceuticals to report change in name and ticker symbol
M2 - Mon Dec 21, 4:39AM CST
Isis Pharmaceuticals (NasdaqGS:ISIS) stated on Friday that it has changed its name to Ionis Pharmaceuticals effective December 2015.
ISIS: 57.56 (-0.28)
Isis Pharmaceuticals changes name to Ionis
AP - Fri Dec 18, 11:19AM CST
NEW YORK (AP) — Isis Pharmaceuticals Inc., which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting to do so for some time.
ISIS: 57.56 (-0.28)
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
PR Newswire - Fri Dec 18, 8:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced "eye-OH-nis"
Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases. ISIS: 57.56 (-0.28)
Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
PR Newswire - Thu Dec 17, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston.
ISIS: 57.56 (-0.28)
Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Brian Orelli, The Motley Fool - Motley Fool - Mon Dec 14, 7:40PM CST
Next year is shaping up to be a great year for emerging biotech Alnylam Pharmaceuticals . The drugmaker expects to have 10 major clinical readouts in 2016. That's more than some one-drug-wonder biotechs have during their entire existence. The...
ISIS: 57.56 (-0.28), ALNY: 62.18 (+0.66)
7 Companies We'd Buy and Hold for the Next 20 Years
Dan Caplinger, Jason Hall, Andrés Cardenal, Steve Symington, Timothy Green, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Dec 14, 4:01PM CST
Many traders hope to get rich quick in the stock market, but over time, the best performance has come from long-term investors who choose companies that can produce solid returns year after year. The key is finding stocks that have the potential for...
AMZN: 745.81 (+9.24), ISIS: 57.56 (-0.28), IBM: 154.46 (+1.86), CMG: 399.71 (+8.93), XLK: 44.13 (+0.68), CVS: 96.74 (+1.24), MA: 88.56 (+0.75)
Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study
Zacks Equity Research - Zacks Investment Research - Mon Dec 14, 3:35PM CST
Isis Pharmaceuticals (ISIS) announced that Biogen has started a phase I/II study on ISIS-SOD1Rx for the treatment of patients with amyotrophic lateral sclerosis.
BIIB: 251.30 (+4.03), ISIS: 57.56 (-0.28), ACHN: 9.14 (+0.26), GSK: 43.38 (+0.04)
Isis Pharmaceuticals begins Phase 1/2 clinical study of ISIS-SOD1 Rx in ALS patients
M2 - Mon Dec 14, 5:10AM CST
Drug discovery company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the launch of a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS) by its partner, Biogen.
ISIS: 57.56 (-0.28)
World Amyloidosis Therapeutics Pipeline Report 2015 - 13 Companies & 25 Drug Profiles
M2 - Fri Dec 11, 6:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/65kjj8/amyloidosis) has announced the addition of the "Amyloidosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bellus Health Inc. - Bsim2 - Celgene Corporation - GlaxoSmithKline Plc - Isis Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - Prothena Corporation Plc - SOM Innovation Biotech SL Drug Profiles - ALN-TTRsc02 - Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - carfilzomib - CLR-01 - eprodisate disodium - GSK-2315698 GSK-2398852 - GSK-2398852 - ISIS-TTRRx - ixazomib citrate - LUNAR-101 - LUNAR-102 - Monoclonal Antibody for Amyloidosis - Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - NEOD-001 - NPT-005 - patisiran - pomalidomide - PTI-110 - revusiran - Small Molecules for AL Amyloidosis - Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - tafamidis meglumine - tolcapone For more information visit http://www.researchandmarkets.com/research/65...myloidosis
ISIS: 57.56 (-0.28), PFE: 36.12 (+0.35), GSK: 43.38 (+0.04), PRTA: 44.01 (+2.28), CELGZ: 1.43 (+0.08)
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
PR Newswire - Fri Dec 11, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis' strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, previously referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents approximately 10 percent of all cases of ALS. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.
ISIS: 57.56 (-0.28)
Positive Clinical Data Sends Isis Pharmaceuticals, Inc. Soaring in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 10, 7:28AM CST
Shares of Isis Pharmaceuticals , a predominantly clinical-stage antisense drug developer, soared 27% in November, based on data from S&P Capital IQ , after reporting an abundance of positive trial outcomes. The biggest boost for Isis...
BIIB: 251.30 (+4.03), ISIS: 57.56 (-0.28)
27.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Dec 09, 9:33AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on October 26th, 2015 at $45.88. In approximately 1 month, Isis Pharmaceuticals has returned 27.02% as of today's recent price of $58.27.
ISIS: 57.56 (-0.28)
Muscular Dystrophy Global Clinical Trials - Analysis, Review, Technologies & Forecast Report H2, 2015
M2 - Tue Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/nb9xbn/muscular) has announced the addition of the "Muscular Dystrophy Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Muscular Dystrophy Global Clinical Trials Review, H2, 2015" provides an overview of Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - aTyr Pharma, Inc. - Pfizer Inc. - Bioblast Pharma Ltd. - Santhera Pharmaceuticals Holding AG - Isis Pharmaceuticals, Inc. - Genethon - AMO Pharma Limited - Alkeus Pharmaceuticals, Inc. - Alfa Wassermann S.p.A - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/nb9xbn/muscular
ISIS: 57.56 (-0.28), PFE: 36.12 (+0.35), XLRN: 34.75 (+0.84)
